MUFG Americas Holdings Corp bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, Holdings Channel reports. The fund bought 499 shares of the life sciences company’s stock, valued at approximately $183,000.
A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Capital International Investors bought a new stake in shares of Illumina in the 3rd quarter valued at $1,482,837,000. Canada Pension Plan Investment Board boosted its stake in shares of Illumina by 272.2% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,023,452 shares of the life sciences company’s stock valued at $375,668,000 after purchasing an additional 748,500 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Illumina by 12.3% in the 3rd quarter. Jennison Associates LLC now owns 4,826,216 shares of the life sciences company’s stock valued at $1,771,511,000 after purchasing an additional 528,635 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Illumina by 219.8% in the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after purchasing an additional 377,283 shares during the last quarter. Finally, WCM Investment Management CA bought a new stake in shares of Illumina in the 3rd quarter valued at $77,035,000. 88.91% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on the stock. UBS Group assumed coverage on shares of Illumina in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price objective on the stock. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Deutsche Bank upped their price objective on shares of Illumina to $350.00 and gave the company a “buy” rating in a research note on Friday, October 12th. Finally, Piper Jaffray Companies upped their price objective on shares of Illumina to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, October 2nd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $330.94.
Shares of NASDAQ ILMN opened at $326.46 on Friday. The firm has a market cap of $47.99 billion, a P/E ratio of 81.62, a P/E/G ratio of 2.42 and a beta of 1.09. Illumina, Inc. has a 12-month low of $207.51 and a 12-month high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. Illumina’s revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 earnings per share. Equities research analysts predict that Illumina, Inc. will post 5.75 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.themarketsdaily.com/2018/12/16/mufg-americas-holdings-corp-buys-new-holdings-in-illumina-inc-ilmn.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Read More: Short Selling Stocks, A Beginner’s Guide
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.